文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

欧洲和加拿大呼吸治疗的碳足迹：CARBON 项目的一项观察性研究。

The carbon footprint of respiratory treatments in Europe and Canada: an observational study from the CARBON programme.

机构信息

Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden

BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.

出版信息

Eur Respir J. 2022 Aug 10;60(2). doi: 10.1183/13993003.02760-2021. Print 2022 Aug.

DOI:10.1183/13993003.02760-2021
PMID:35777767
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9363844/
Abstract

https://bit.ly/3zh3c2B

摘要

https://bit.ly/3zh3c2B

相似文献

[1]
The carbon footprint of respiratory treatments in Europe and Canada: an observational study from the CARBON programme.

Eur Respir J. 2022-8

[2]
Convergence in CO emissions, carbon footprint and ecological footprint: evidence from OECD countries.

Environ Sci Pollut Res Int. 2019-1-7

[3]
The carbon footprint of cataract surgery.

Eye (Lond). 2013-2-22

[4]
Carbon footprint: current methods of estimation.

Environ Monit Assess. 2010-9-18

[5]
Carbon: Resolve ambiguities in China's emissions.

Nature. 2015-9-24

[6]
Carbon footprint of patient journeys.

Br J Gen Pract. 2013-10

[7]
Carbon footprint associated with four disposal scenarios for urban pruning waste.

Environ Sci Pollut Res Int. 2017-11-4

[8]
The Carbon Footprint of Residency Interviews.

Acad Med. 2021-7-1

[9]
China's carbon emissions overestimated.

Nature. 2015-8-20

[10]
Carbon footprint of robotically-assisted laparoscopy, laparoscopy and laparotomy: a comparison.

Int J Med Robot. 2015-12

引用本文的文献

[1]
Trends in inhaler use and associated carbon footprint: a sales data-based study in Europe.

BMJ Open Respir Res. 2025-9-1

[2]
Carbon Footprint Impact, of Monoclonal Antibodies for Severe Asthma, Administered in Italy.

Biomedicines. 2025-6-27

[3]
Comparing the CO emissions of metered dose inhalers and dry powder inhalers: a cross-sectional environmental impact analysis of asthma and COPD therapies in South Tyrol, Italy.

BMJ Open Respir Res. 2025-6-27

[4]
Estimated carbon emissions for PBS-subsidised prescription respiratory inhalers, Australia, 2019-2023: a descriptive analysis.

Med J Aust. 2025-6-26

[5]
Exploring the carbon footprint of severe asthma and change after biologic therapy initiation: an analysis of Northern Irish data.

ERJ Open Res. 2025-6-23

[6]
How to reduce carbon footprints in asthma.

ERJ Open Res. 2025-6-23

[7]
Utilization and access to metered-dose inhalers and sustainable alternatives among older adults in the United States: a population-based study.

Lancet Reg Health Am. 2025-6-5

[8]
How to move towards more sustainable asthma care in Europe: an expert opinion paper.

Breathe (Sheff). 2025-5-13

[9]
Environmental impact of inhaled medicines: A Thoracic Society of Australia and New Zealand position statement.

Respirology. 2025-2

[10]
Climate-conscious inhaler prescribing for family physicians.

Can Fam Physician. 2024-6

本文引用的文献

[1]
Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America.

J Allergy Clin Immunol Pract. 2022-9

[2]
Environmental Sustainability in Respiratory Care: An Overview of the healthCARe-Based envirONmental Cost of Treatment (CARBON) Programme.

Adv Ther. 2022-5

[3]
The Burden of Short-Acting β-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program.

Adv Ther. 2021-7

[4]
Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany.

Respir Res. 2021-4-16

[5]
Health care's response to climate change: a carbon footprint assessment of the NHS in England.

Lancet Planet Health. 2021-2

[6]
Asthma-Related Health Outcomes Associated with Short-Acting β-Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global Program.

Adv Ther. 2020-10

[7]
Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK.

Eur Respir J. 2020-6

[8]
SABINA: An Overview of Short-Acting β-Agonist Use in Asthma in European Countries.

Adv Ther. 2020-1-24

[9]
Overuse of short-acting β-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme.

Eur Respir J. 2020-4-16

[10]
SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β-agonist use in asthma.

Eur Respir J. 2020-2-12

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索